Athersys, Inc. (ATHX) Awarded Patent Protection for MultiStem Product Platform, adding to Current IP Portfolio
Clinical stage biopharmaceutical company Athersys Inc. today announced it has been granted a patent that covers the company’s proprietary cell therapy product, MultiStem®. MultiStem is an investigational stem cell therapy with demonstrated therapeutic potential to treat a broad range of indications in the cardiovascular, neurological, and inflammatory and immune condition disease areas. The patent covers the use of non-embryonic multipotent stem cells for the treatment of cardiovascular conditions, including heart attack and congestive heart failure. The patent also provides protection for several techniques of stem cell delivery for the treatment of such conditions. "Cardiovascular disease represents an important opportunity area…